Synonym
Indoxole; U 22020; U-22020; U22020
IUPAC/Chemical Name
2,3-bis(4-methoxyphenyl)-1H-indole
InChi Key
SRETXDDCKMOQNE-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H19NO2/c1-24-17-11-7-15(8-12-17)21-19-5-3-4-6-20(19)23-22(21)16-9-13-18(25-2)14-10-16/h3-14,23H,1-2H3
SMILES Code
COC1=CC=C(C2=C(C3=CC=C(OC)C=C3)NC4=C2C=CC=C4)C=C1
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
329.40
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Lednicer D. Tracing the origins of COX-2 inhibitors' structures. Curr Med Chem. 2002 Aug;9(15):1457-61. Review. PubMed PMID: 12173976.
2: Collier HO, James GW, Piper PJ. Antagonism by fenamates and like-acting drugs of bronchoconstriction induced by bradykinin or antigen in the guinea-pig. Br J Pharmacol. 1968 Sep;34(1):76-87. PubMed PMID: 5676040; PubMed Central PMCID: PMC1703405.
3: Spinelli HM, Krohn DL. Inhibition of prostaglandin-induced iritis. Topical indoxole vs indomethacin therapy. Arch Ophthalmol. 1980 Jun;98(6):1106-9. PubMed PMID: 7387517.
4: Smolin G, Okumoto M, Hall JM, Friedlaender M. The effect of indoxole on the corneal immunologic response. Ann Ophthalmol. 1979 Feb;11(2):227-232. PubMed PMID: 86318.
5: Podos SM, Becker B. Comparison of ocular prostaglandin synthesis inhibitors. Invest Ophthalmol. 1976 Oct;15(10):841-4. PubMed PMID: 977253.
6: Schaeffer HE, Krohn DL. Liposomes in topical drug delivery. Invest Ophthalmol Vis Sci. 1982 Feb;22(2):220-7. PubMed PMID: 7056633.
7: Glenn EM, Bowman BJ, Kooyers W, Koslowske T, Myers ML. The pharmacology of 2,3-bis-(p-methoxyphenyl)-indole (indoxole). J Pharmacol Exp Ther. 1967 Jan;155(1):157-66. PubMed PMID: 6017336.
8: Whitehouse MW. Evaluation of potential antirheumatic drugs in vitro using lymphocytes and epithelial cells. The selective action of indoxole, methyl glyoxal and chloroquine. J Pharm Pharmacol. 1967 Sep;19(9):590-5. PubMed PMID: 4383451.
9: Wagner JG, Gerard ES, Kaiser DG. The effect of the dosage form on serum levels of indoxole. Clin Pharmacol Ther. 1966 Sep-Oct;7(5):610-9. PubMed PMID: 5957166.
10: Kaiser DG, Bowman BJ, Forist AA. Fluorometric determination of indoxole [2,3-bis-(p-methoxyphenyl)-indole] in biological specimens. Anal Chem. 1966 Jul;38(8):977-80. PubMed PMID: 5941080.
11: Kaiser DG, Glenn EM, Johnson RH, Johnston RL. Correlation of serum indoxole [2,3-bis(p-methoxyphenyl)-indole] levels with biologic activity. J Pharmacol Exp Ther. 1967 Jan;155(1):174-80. PubMed PMID: 4959694.
12: Steele AD, McCarty DJ Jr. Suppressive effects of indoxole in crystal-induced synovitis in man. Ann Rheum Dis. 1967 Jan;26(1):39-42. PubMed PMID: 5334568; PubMed Central PMCID: PMC1030996.
13: Podos SM. Prostaglandins, nonsteroidal anti-inflammatory agents and eye disease. Trans Am Ophthalmol Soc. 1976;74:637-60. PubMed PMID: 194383; PubMed Central PMCID: PMC1311530.
14: Bhattacherjee P, Eakins KE. Inhibition of the ocular effects of sodium arachidonate by anti-inflammatory compounds. Prostaglandins. 1975 Feb;9(2):175-82. PubMed PMID: 1135434.
